HomeAI · summaries
Storia in 2 fonti
Traws Pharma influenza challenge study deferred following MHRA review
Traws Pharma (TRAW) announced that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to...
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
Traws Pharma influenza challenge study deferred following MHRA review
Traws Pharma (TRAW) announced that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to...
- ·
benzinga.com
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Traws Pharma (NASDAQ:TRAW)
Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.